TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03200067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized health care service
Description: Personalized health care service, such as rehabilitation exercise recommendation, lifestyle activity coaching, health data monitoring
Study: NCT04590300

Intervention type: OTHER
Group type: OTHER
Intervention: QUESTIONNAIRES
Description: 1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE

Intervention type: OTHER
Group type: OTHER
Intervention: QUESTIONNAIRES
Description: 1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE
Study: NCT02520505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supraovulation clomiphene citrate
Description: Treatment with clomiphene citrate during day 3 to 7 of the menstrual cycle.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Timed intercourse
Description: Timing intercourse during the fertile window in the menstrual cycle. Patients may also utilize an ovulation predictor kit to determine time of ovulation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine Insemination
Description: Intrauterine insemination will be performed \~36 hours after the time the woman ovulates, as determined by an ovulation predictor kit.
Study: NCT02849652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATTOC Intervention
Description: ATTOC is implemented in a systematic 3-phase process with 10 steps to guide sites through cultural change and implementation of evidence-based practice.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: UC Intervention
Description: Sites randomized to UC will not receive an organizational intervention to address TUD treatment. To ensure standardization across UC sites, study personnel will provide a 1-day training seminar that will include written materials describing recommended treatments for TUD to UC personnel consistent with established treatment guidelines.
Study: NCT01436032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study: NCT04296903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MID-C System
Description: Minimal invasive deformity correction system for the treatment of AIS
Study: NCT03456570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone 10 mg
Description: Dydrogesterone 10 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: oral tablets twice daily
Study: NCT00760266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg for 1 week, Aliskiren 300 mg (with or without amlodipine)for 7 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide (HCTZ) 12.5 mg for week 1; Hydrochlorothiazide (HCTZ) 25 mg (with or without amlodipine)for 7 weeks
Study: NCT02223000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBV 308 SE solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBV 308 SE capsule 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBV 308 SE capsule 2
Study: NCT03629249

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo once daily
Description: Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 150 mg and one tablet blinded placebo to QAW039 450 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039 150 mg once daily
Description: QAW039 150 mg once daily (one tablet of blinded QAW039 150 mg to be given together with one tablet blinded placebo to QAW039 450 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039 450 mg once daily
Description: QAW039 450 mg once daily (one tablet of blinded QAW039 450 mg to be given together with one tablet blinded placebo to QAW039 150 mg)
Study: NCT01622998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NicoDerm Patch
Description: Dosage: 21mg patch; 14mg patch; 7 mg patch Frequency: NRT patch application once per day Duration: 10 week treatment period~\*Titration for experimental group (NRT+) based on smoking history, and option to increase dose if withdrawal symptoms are unmanageable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NicoDerm Patch
Description: Dosage: 21mg patch; 14mg patch; 7 mg patch Frequency: NRT patch application once per day Duration: 10 week treatment period~\*Titration for experimental group (NRT+) based on smoking history, and option to increase dose if withdrawal symptoms are unmanageable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Inhaler
Description: Nicorette Inhaler: Box, 42 cartridges (4mg/cartridge) Dosage: Ad libitum Maximum dosage: 6-12 cartridges/day
Study: NCT03581448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Restoration During Prosthesis Control
Description: Human subjects who use a robotic arm/hand interface will experience variable sensations of touch over time.
Study: NCT01402908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88
Description: Lyophilized powder reconstituted to provide 160 mg of PI-88

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose lyophilized powder
Study: NCT03104166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medium Cut-Off (MCO) dialysis membrane
Description: Patients will be treated with a CE-certified dialysis membrane that provide enhanced clearance for middle-sized molecules, call Medium Cut-Off membrane.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Flux dialysis membrane
Description: Control: Patients will be treated with a CE-certified High-Flux dialysis membrane.
Study: NCT04792944

Intervention type: DRUG
Intervention: Urokinase
Description: Washing the subarachnoid clot induced by a subarachnoid haemorrhage aneurysmal bleeding with urokinase after aneurysm clipping

Intervention type: PROCEDURE
Intervention: Endovascular treatment
Description: Aneurysm treatment through endovascular methods

Intervention type: PROCEDURE
Intervention: Clipping
Description: Surgical clipping of brain aneurysms

Intervention type: PROCEDURE
Intervention: Clipping
Description: Surgical clipping of brain aneurysms

Intervention type: PROCEDURE
Intervention: Clipping
Description: Surgical clipping of brain aneurysms

Intervention type: PROCEDURE
Intervention: External ventricular drain
Description: Insertion of an external ventricular drain to treat acute hydrocephalus
Study: NCT02980978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Focus on nutrition, activity and appropriate medication use and adherence
Study: NCT06134778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training was performed for six weeks. Athletes performed two daily sessions of 30 forced inspirations followed by long but not maximal expirations, with load adjusted between 50% and 60% of maximum inspiratory pressure, five times a week. A specific device was used for this purpose (Classic, Powerbreathe, United Kingdom), with light or medium resistance adjustment, depending on the subject's maximum inspiratory pressure.
Study: NCT04486196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medency Primo Diode Laser Device (Medency, Vicenza, Italy)
Description: Root canals were irradiated with 980 nm diode laser coupled with optical fiber 200 µm with setting at the average power 1.2-W in pulsed mode. 10 seconds irradiation followed by 10 seconds pause, which comprised one lasting cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl, %17 EDTA, Distilled water, 30-gauge, side-opening needle (Canal Clean, Biodent, South Korea),
Description: Final conventional irrigation
Study: NCT01626079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip System
Description: Percutaneous mitral valve repair using MitraClip System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip System
Description: Percutaneous mitral valve repair using MitraClip System
Study: NCT03371290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: The healthy UE will be positioned in front of the mirror and the paretic UE behind it, enabling the patient to observe the movements of the healthy limb through the mirror, interpreting that image as the affected limb. The MT protocol will be composed of active bimanual exercises of range of motion and functional exercises. Three sets of 15 repetitions will be performed for each exercise with a 20 seconds interval between each series, for 30 minutes. The exercises: 1) Elbow flexion/extension; 2) Wrist flexion/extension in neutral position; 3) Fingers flexion/extension in neutral position; 4) Forearm pronation/supination; 5) Roll the ball with hands; 6) Squeezing the sponge; 7) Drag a towel in anteroposterior direction; 8) Opponency of fingers; 9) Climb the mirror with the fingers (similar to walking the spider).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: In the control intervention, patients will be performed the same bimanual activities proposed by the MT protocol, but without the reflector side of the mirror. The mirror will be placed in the same position as the MT intervention. However, the subject will have access to the non-reflective side of the mirror, directly visualizing the movement of his healthy arm.~Both interventions will be performed a single session of MT or control composed of 30 minutes of exercises. The participants who will be first assigned to the MT intervention, after 4-weeks washout period, will be performed the same procedures, but in the control intervention. Likewise, patients who will be first allocated to control intervention, after 4-weeks of washout, will be performed the same procedures, however in MT intervention.
Study: NCT04552509

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy
Description: Treatment of prostate cancer with stereotactic body radiation therapy (SBRT)
Study: NCT03210636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LapSpace
Description: use of atraumatic laparoscopic retractor for patients undergoing laparoscopic surgery
Study: NCT01807637

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stim (tDCS)
Description: During anodal tDCS, participants will receive 20 min at 2mA over motor cortex (with 30 seconds of ramp-up and ramp-down). During sham stimulation the stimulator is turned off.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stim (tDCS)
Description: During anodal tDCS, participants will receive 20 min at 2mA over motor cortex (with 30 seconds of ramp-up and ramp-down). During sham stimulation the stimulator is turned off.
Study: NCT01756937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imotun
Description: 300.03mg/cap,orally, 1 capsule once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule once daily for 24 weeks
Study: NCT01255878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: occlusal stabilization splint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentine
Description: 100 mg(1 capsule)three times per day for two months
Study: NCT02850770

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pedometers and Walking Logs
Description: Participants were recommended to use the pedometer and walking log to self-monitor how many steps participants walked each day. Participants were recommended to gradually increase daily steps over the course of 12 weeks until reaching 10,000 steps per day. Participants were also recommended to walk at a brisk pace for 3000 of these steps, which roughly translates to 30 minutes per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometers and Walking Logs
Description: Participants were recommended to use the pedometer and walking log to self-monitor how many steps participants walked each day. Participants were recommended to gradually increase daily steps over the course of 12 weeks until reaching 10,000 steps per day. Participants were also recommended to walk at a brisk pace for 3000 of these steps, which roughly translates to 30 minutes per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometers and Walking Logs
Description: Participants were recommended to use the pedometer and walking log to self-monitor how many steps participants walked each day. Participants were recommended to gradually increase daily steps over the course of 12 weeks until reaching 10,000 steps per day. Participants were also recommended to walk at a brisk pace for 3000 of these steps, which roughly translates to 30 minutes per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Messaging
Description: Participants received short text or voice messages (depending on participant preference) as reminders to review daily step goals and to self-monitor; explaining the benefits of regular physical activity, importance of regular physical activity to daily life, and ways to overcome commonly identified barriers to physical activity; asking participants to report on their physical activity performance; providing feedback based on responses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Messaging
Description: Participants received short text or voice messages (depending on participant preference) as reminders to review daily step goals and to self-monitor; explaining the benefits of regular physical activity, importance of regular physical activity to daily life, and ways to overcome commonly identified barriers to physical activity; asking participants to report on their physical activity performance; providing feedback based on responses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family/Friend Support
Description: Participants identified a family member or close friend (FF) to receive short text or voice messages (depending on FF preference) with suggested behaviors that are perceived as supportive by individuals making physical activity behavior changes.
Study: NCT03474510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local infiltration of liposomal bupivacaine
Description: Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous infusion of ropivacaine interscalene nerve block
Description: All patients will receive a single injection of 30mL, 0.5% preservative-free ropivacaine.~Those patients randomized to receive CINB will then have an indwelling catheter placed and held in place by Dermabond and Tegaderm. Placement will be confirmed by ultrasound. Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer.
Study: NCT04320173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 1.8%
Description: Three patches are applied to the subject's back for 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 1.8%
Description: Three patches are applied to the subject's back for 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 1.8%
Description: Three patches are applied to the subject's back for 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Description: Three patches are applied to the subject's back for 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Description: Three patches are applied to the subject's back for 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Description: Three patches are applied to the subject's back for 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine medicated plaster 5%
Description: Three plasters are applied to the subject's back for 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine medicated plaster 5%
Description: Three plasters are applied to the subject's back for 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine medicated plaster 5%
Description: Three plasters are applied to the subject's back for 12 hours.
Study: NCT00821028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery. Dosing will be based on ther lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm\^3
Study: NCT04328532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI examination (45 min max) with potential oxygen delivery for 10 min
Study: NCT04118478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multi-component phased training program
Description: The experimental group will develop a program that consists of three progressive phases with the predominance of one physical quality over the others. The first phase will have as its main objective to develop strength, through exercises with overload and in turn, it will be subdivided into 3 blocks of 3 weeks each: Neuromuscular adaptation, muscular power, muscular resistance. The second phase will have as its main objective to develop cardiorespiratory capacity through intermittent gait training and, in turn, will be subdivided into 3 blocks of 3 weeks each: Static gait, dynamic gait and dynamic gait with changes of direction. The last phase will have as its main objective to develop balance and flexibility, by strengthening the stabilizing muscles and range of motion. In turn, this phase will be subdivided into 3 blocks of 3 weeks each: Balance / static flexibility, balance / dynamic flexibility and balance / flexibility with a double task.
Study: NCT01867723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet communication application
Description: Intervention 1 Effect of internet support program will be tested on cancer patients and their family caregivers No intervention
Study: NCT00535808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitroprusside
Description: Administration of nitroprusside

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitroglycerine
Description: Administration of nitroglycerine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Administration of Sevoflurane
Study: NCT02512978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
Study: NCT04029610

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthesia with lidocaine and adrenalin.
Description: Local anesthesia with lidocaine and adrenalin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine and adrenalin
Description: lidocaine and adrenalin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine and arterial blockage
Description: lidocaine and arterial blockage
Study: NCT01565096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride at individual dose
Study: NCT00419770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Description: 20 mg/kg enterally per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liposomal amphotericin B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Study: NCT01724502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and muscle biopsies
Description: Subjects will undergo a euglycemic clamp, VO_2 max determination, exercise periods and muscle biopsies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and muscle biopsies
Description: Subjects will undergo a euglycemic clamp, VO_2 max determination, exercise periods and muscle biopsies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and muscle biopsies
Description: Subjects will undergo a euglycemic clamp, VO_2 max determination, exercise periods and muscle biopsies.
Study: NCT00818337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg and Aspirin 325mg, non-enteric coated, take one tablet by mouth daily